Fig. 5From: Benefits of near-universal vaccination and treatment access to manage COVID-19 burden in the United StatesAnnual burden across all ages between 2025 and 2033 given age-specific vaccination when immune duration is 548-day. The targeted age group (on x-axis) has 25% higher vaccination coverage than the vaccination coverage applied on other age groups. The current vaccination coverage is 49%. The treatment coverage through the entire period is 13.7%Back to article page